Novavax avian flu vaccine shows promise

Novavax (NVAX) says preclinical data published in a peer reviewed journal show the company's A(H7N9) VLP vaccine provided "100% protection against lethal wild-type A(H7N9) influenza challenge versus 0% survival in control (H5N1) vaccine" in mouse models.

The efficacy data may "support clinical development of an H7N9 VLP vaccine."

NVAX shares +3.6% premarket.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs